最近KRAS-G12C抑制剂在癌症治疗中的进展
Mengqi Li1, Huan Wang2, Fei Wang3
1Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China.
European journal of medicinal chemistry
|June 24, 2025
概括
克拉斯G12C抑制剂是癌症治疗的关键药物. 本综述探讨了开发新型KRAS G12C抑制剂的药物化学策略,以克服耐药性并改善癌症治疗.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药用化学 医学化学
背景情况:
- 拉斯基因家族,特别是克拉斯基因,是细胞信号传递和癌症发展的核心.
- KRAS突变,特别是G12C,在人类癌症中很普遍,导致不受控制的增殖和转移.
- 向KRAScoproteins是癌症治疗中的一个关键策略.
研究的目的:
- 为开发KRAS G12C抑制剂提供当前药物化学方法的概述.
- 为突出KRAS G12C抑制剂设计中的创新.
- 为未来针对KRAS G12C的治疗开发提供框架.
主要方法:
- 对当代药用化学文献的综述.
- 对KRAS G12C抑制剂药物开发策略的分析.
- 综合现有研究和临床数据的见解.
主要成果:
- 开发KRAS G12C抑制剂,如索托拉西布 (AMG510),已经显示出承诺.
- 新兴的抗药性机制需要持续的药物化学努力.
- 许多KRAS G12C抑制剂正处于临床开发的各个阶段.
结论:
- 药物化学在推进KRAS G12C向治疗中发挥着至关重要的作用.
- 了解抵抗机制是设计下一代抑制剂的关键.
- 本综述为开发针对KRAS G12C驱动癌症的新疗法提供了有价值的见解.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.4K
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.1K
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
M-Cdk Drives Transition Into Mitosis
5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
